Top

Published in:

07-04-2022 | Breast Cancer | Original Article

Comparing single or dual tracing modality on sentinel lymph node biopsy from patients who plan to omitting axillary lymph node dissection referring to the criteria of Z0011 trial: a retrospective study

Authors: Yingchun Xu, Hanjin Wu, Wei Zhang, Yupeng Shen, Yujie Jiang, Liwei Meng

Published in: Updates in Surgery | Issue 3/2022

Abstract

Axillary lymph node dissection (ALND) can be omitted in the part of the breast-conserving patients with positive sentinel lymph nodes (SLNs) since Z0011 trial has presented. Nevertheless, to date, no studies revealed the influence of different tracing modalities (single tracer versus dual tracers) for sentinel lymph node biopsy (SLNB) on axillary management referring to Z0011 trial criteria. This study aimed to assess whether different tracing modalities of SLNB have impact on axillary management referring to Z0011 trial criteria. The clinical data of breast-conserving patients who underwent SLNB guided by combination of methylene blue (MB) and indocyanine green(ICG) were retrospectively analyzed in our center. The numbers of metastatic (positive) SLNs guided by the single tracer and the dual tracer were compared by self-control study. 127 patients with 1–2 metastatic SLNs dyed by MB [(recorded as MB(+))]were retrieved from our database between 2016 and 2020. In these cases, 53 patients contained 86 SLNs, which were ICG staining but MB negative staining (recorded as ICG(+)/MB(−)). In addition, 16 patients contained 20 metastatic SLNs with ICG(+)/MB(−). There were six patients finally excluded patients (6/127, 4.7%) who initially met the criteria of Z0011 trial, because the further detection of ICG(+)/MB(−) SLNs led the total numbers of positive SLNs over two. The difference was statistically significant. Single tracing modality may underestimate the positive SLN numbers compared to dual tracing modality. Different tracing modalities of SLNB will significantly affect Axillary management referring to Z0011 trial criteria.

Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the acosog z0011 (alliance) randomized clinical trial. JAMA 318(10):918–926. https://doi.org/10.1001/jama.2017.11470CrossRefPubMedPubMedCentral

Morigi C, Peradze N, Galimberti V et al (2020) Feasibility and surgical impact of Z0011 trial criteria in a single-Institution practice. Breast J 26(7):1330–1336. https://doi.org/10.1111/tbj.13851CrossRefPubMed

Liu M, Wang S, Cui S, Duan X, Fan Z, Yu Z (2015) The feasibility of the ACOSOG Z0011 criteria to Chinese breast cancer patients: a multicenter study. Sci Rep 5:15241. https://doi.org/10.1038/srep15241CrossRefPubMedPubMedCentral

Kittaka N, Tokui R, Ota C et al (2018) A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery. Int J Clin Oncol 23(5):860–866. https://doi.org/10.1007/s10147-018-1297-0CrossRefPubMed

Inoue T, Nishi T, Nakano Y et al (2016) Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer. Breast Cancer 23(2):295–300. https://doi.org/10.1007/s12282-014-0573-8CrossRefPubMed

Guo J, Yang H, Wang S et al (2017) Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study. World J Surg Oncol 15(1):196. https://doi.org/10.1186/s12957-017-1264-7CrossRefPubMedPubMedCentral

Varghese P, Abdel-Rahman AT, Akberali S, Mostafa A, Gattuso JM, Carpenter R (2008) Methylene blue dye–a safe and effective alternative for sentinel lymph node localization. Breast J 14(1):61–67. https://doi.org/10.1111/j.1524-4741.2007.00519.xCrossRefPubMed

Somashekhar SP, Kumar CR, Ashwin KR et al (2020) Can low-cost indo cyanine green florescence technique for sentinel lymph node biopsy replace dual dye (radio-colloid and blue dye) technique in early breast cancer: a prospective two-arm comparative study. Clin Breast Cancer 20(5):e576–e583. https://doi.org/10.1016/j.clbc.2020.03.013CrossRefPubMed

Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881–888. https://doi.org/10.1016/S1470-2045(07)70278-4CrossRefPubMed

10.

Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10):927–933. https://doi.org/10.1016/S1470-2045(10)70207-2CrossRefPubMedPubMedCentral

11.

Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310. https://doi.org/10.1016/S1470-2045(14)70460-7CrossRefPubMedPubMedCentral

12.

Borm KJ, Oechsner M, Düsberg M et al (2020) Irradiation of regional lymph node areas in breast cancer — Dose evaluation according to the Z0011, AMAROS, EORTC 10981–22023 and MA-20 field design. Radiother Oncol 142:195–201. https://doi.org/10.1016/j.radonc.2019.08.021CrossRefPubMed

13.

Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23(30):7703–7720. https://doi.org/10.1200/JCO.2005.08.001CrossRefPubMed

14.

Komoike Y, Inokuchi M, Itoh T et al (2015) Japan Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer. Breast Cancer 22(1):37–48. https://doi.org/10.1007/s12282-014-0558-7CrossRefPubMed

15.

Lucci A Jr, Kelemen PR, Miller C 3rd, Chardkoff L, Wilson L (2001) National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 192(4):453–458. https://doi.org/10.1016/s1072-7515(01)00798-0CrossRefPubMed

16.

Li J, Chen X, Qi M, Li Y (2018) Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: a systematic review and meta-analysis. PLoS ONE 13(9):e0204364. https://doi.org/10.1371/journal.pone.0204364CrossRefPubMedPubMedCentral

17.

Wang C, Tong F, Cao Y et al (2021) Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-021-06196-6CrossRefPubMedPubMedCentral

18.

Wang Z, Cui Y, Zheng M et al (2020) Comparison of indocyanine green fluorescence and methylene blue dye in the detection of sentinel lymph nodes in breast cancer. Gland Surg 9(5):1495–1501. https://doi.org/10.21037/gs-20-671CrossRefPubMedPubMedCentral

19.

Shen S, Xu Q, Zhou Y, Mao F, Guan J, Sun Q (2018) Comparison of sentinel lymph node biopsy guided by blue dye with or without indocyanine green in early breast cancer. J Surg Oncol 117(8):1841–1847. https://doi.org/10.1002/jso.25058CrossRefPubMed

20.

Yi M, Meric-Bernstam F, Ross MI et al (2008) How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer 113(1):30–37. https://doi.org/10.1002/cncr.23514CrossRefPubMed

21.

Ban EJ, Lee JS, Koo JS, Park S, Kim SI, Park BW (2011) How many sentinel lymph nodes are enough for accurate axillary staging in t1–2 breast cancer? J Breast Cancer 14(4):296–300. https://doi.org/10.4048/jbc.2011.14.4.296CrossRefPubMedPubMedCentral

Title: Comparing single or dual tracing modality on sentinel lymph node biopsy from patients who plan to omitting axillary lymph node dissection referring to the criteria of Z0011 trial: a retrospective study
Authors: Yingchun Xu
Hanjin Wu
Wei Zhang
Yupeng Shen
Yujie Jiang
Liwei Meng
Publication date: 07-04-2022
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Published in: Updates in Surgery / Issue 3/2022
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-022-01285-7

At a glance: The STEP trials

Springer Medicine

Comparing single or dual tracing modality on sentinel lymph node biopsy from patients who plan to omitting axillary lymph node dissection referring to the criteria of Z0011 trial: a retrospective study

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Effect of hyaluronate-based bioresorbable membrane (Seprafilm) on outcomes of abdominal surgery: a meta-analysis and trial sequential analysis of randomised controlled trials

Laparoscopic right colectomy: changes in surgical technique and perioperative management allow better postoperative results in a comparative series of 361 patients

Primary closure versus T-tube drainage after laparoscopic common bile duct exploration in patients with non-severe acute cholangitis

Laparoscopic glissonean pedicle approach: step by step video description of the technique from different centres (with video)

Foreword

The real-word impact of breast and colorectal cancer surgery during the SARS-CoV-2 pandemic